Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20554159 | 1.00 | MEN1 (0.34) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL2839477 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL584255 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL25569891 | 0.86 | PARP1 (0.36) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL2848749 | 0.86 | NR1H2 (0.41) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL18700387 | 0.81 | TSHR (0.33) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL585387 | 0.80 | MEN1 (0.32) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL585388 | 0.80 | MEN1 (0.32) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL12481022 | 0.78 | MEN1 (0.36) | MEN1KMT2ANR1H2CHRM2CHRM1 | |
| SCHEMBL18089591 | 0.78 | MEN1 (0.36) | MEN1KMT2ANR1H2CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) | 2019-01-03 | — | — | US | disclosed |
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | NR1H4, FXR1, GPBAR1 | MEN1 3046/4885KMT2A 3129/4885NR1H2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.